Friday, July 10, 2026

pharma · Weight management · Short Bowel Syndrome

Zealand Pharma

Zealand Pharma clinical programs — 18 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Sydmarken 11, Søborg (Copenhagen), 2860, DK HQ
1998 Founded
596 Employees
EMA registrant Type
Company details
Status
Public
HQ
Sydmarken 11, Søborg (Copenhagen), 2860, DK
Founded
1998
Employees
596
Programs
18
Drugs
20
Patents
0
Intelligence · Clinical Programs

Zealand Pharma projects

18 ClinicalTrials.gov programs sponsored by Zealand Pharma.

Zealand Pharma has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Dasiglucagon 4 mg/ml

    Zealand Pharma A/S

    Children with congenital hyperinsulinism

    phase 3 small molecule active

    1 trial
  2. Early activity and mobilisation

    Zealand Pharma A/S

    Critically Ill, Mechanically Ventilated

    phase 3 other completed

    1 trial
  3. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial
  4. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short bowel syndrome

    phase 3 small molecule active

    1 trial
  5. Glepaglutide 20.0 mg/mL, Glepaglutide Placebo

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial
  6. TARGET protocol EN 1.5 kcal/mL

    Zealand Pharma A/S

    Critical Illness

    phase 3 other completed

    1 trial
  7. ZP1848-23029

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial
  8. Panobinostat

    Zealand Pharma A/S

    Rhabdoid Tumor

    phase 2 small molecule terminated

    1 trial
  9. Pantoprazole 40mg

    Zealand Pharma A/S

    Oncology

    phase 2 small molecule completed

    1 trial
  10. Pembrolizumab plus denosumab

    Zealand Pharma A/S

    Renal Cell Carcinoma, Clear Cell

    phase 2 small molecule active

    1 trial
  11. Vitamin C

    Zealand Pharma A/S

    Shock, Septic

    phase 2 small molecule completed

    1 trial
  12. ZP8396-23094

    Zealand Pharma A/S

    Weight management

    phase 2 small molecule active

    1 trial
  13. Single and multiple ascending dose of ZP9830 in healthy participants

    Zealand Pharma A/S

    Autoimmune diseases

    phase 1 other active

    1 trial
  14. ZP7570-24026

    Zealand Pharma A/S

    Weight management

    phase 1 other active

    1 trial
  15. ZP8396-24059

    Zealand Pharma A/S

    Weight management

    phase 1 other active

    1 trial
  16. ZP8396-25041

    Zealand Pharma A/S

    Weight reduction

    phase 1 other active

    1 trial
  17. ZP8396-25077

    Zealand Pharma A/S

    Healthy / hepatic impaired volunteers only study to assess PK parameters

    phase 1 other active

    1 trial
  18. Ropivacaine

    Zealand Pharma A/S

    Pain, Postoperative

    small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Zealand Pharma have?

18 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.